AML study reports high response rates with combination targeted therapy
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .
The patients, age 60 years or older, received therapy with venetoclax in combination with cobimetinib or idasanutlin. The clinical trial followed...
Phase 2 CAR-T study reports significant remission rates at 15-month follow up
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with...
PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended...
Novel regulation of gene expression in brain tumors identified
Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and spread, according to researchers at The University of Texas MD Anderson Cancer Center.
The study, led by Zhimin Lu, M.D., Ph.D., professor of Neuro-Oncology, identified a previously unreported linkage between two enzymes known as Gcn5 and alpha-ketoglutarate dehydrogenase (alpha-KGDH), providing...
Ribociclib extends progression-free survival in pre-menopausal patients with metastatic hormone receptor-positive breast cancer
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (...
MD Anderson to present key drug study findings for multiple blood cancers at ASH annual meeting
Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers...
Peter WT Pisters, M.D., begins tenure as president of MD Anderson
The University of Texas MD Anderson Cancer Center today welcomes Peter WT Pisters, M.D., as its fifth full-time president in the institution...
MD Anderson applauds court-ordered corrective statements from tobacco industry to educate public about harms of tobacco use
As an institution dedicated to ending cancer, The University of Texas MD Anderson Cancer Center is committed to promoting cancer prevention...
Six researchers from MD Anderson elected as AAAS Fellows
In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas...
Quality of care for older Texas patients with colon cancer on the rise, still room for improvement
Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly...
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
Seres Therapeutics, Inc., The University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy today...
Thousands support MD Anderson’s Boot Walk to End Cancer®
Thousands of patients, family members, volunteers, friends and employees of The University of Texas MD Anderson Cancer Center participated...
Seven leaders join MD Anderson Cancer Center Board of Visitors
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) welcomed seven new members at its annual meeting today. They include...
Chronic stress hormones may promote resistance to EGFR inhibitors in lung cancer patients
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used...
Circulating tumor cells associated with relapse in late-stage melanoma patients
A study revealing a connection between circulating tumor cells (CTCs) and relapse in stage IV melanoma patients points to liquid biopsy as...
MD Anderson’s Moon Shots Program celebrates five-year anniversary
The University of Texas MD Anderson Cancer Center celebrates the five-year anniversary of its Moon Shots Program™, a collaborative effort...
Bacteria in the gut modulates response to immunotherapy in melanoma
Bacteria that live in the human digestive tract can influence how cancer responds to immunotherapy, opening a new avenue for research to improve...
Sarah Ann Roder receives MD Anderson’s highest nursing honor
Sarah Ann Roder, a clinical nurse in the Gynecologic Oncology Outpatient Center at The University of Texas MD Anderson Cancer Center,...
Baytown community launches Be Well™ Baytown initiative led by MD Anderson and ExxonMobil
In an effort to improve public health and lower the risk of cancer, Baytown community organizations are partnering with The University of...
Dream Team aims to intercept pancreatic cancer before it flourishes
Deeply entrenched and mature by the time it’s found, pancreatic cancer is one of the hardest to defeat. A Dream Team assembled by Stand...
MD Anderson Hosts A Conversation With a Living Legend® with philanthropist Rich Kinder
Houston philanthropist Rich Kinder, executive chairman of Kinder Morgan Inc., will join Houston-based NBC News correspondent Janet Shamlian...
Drug yields high response rates for lung cancer patients with harsh mutation
A targeted therapy resurrected by the Moon Shots Program™ at The University of Texas MD Anderson Cancer Center has produced unprecedented...
V. Craig Jordan, Ph.D., elected to the National Academy of Medicine
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been elected to the National Academy of Medicine for his discovery of selective...
Cattlemen for Cancer Research to host annual auction Oct. 21
Cattlemen for Cancer Research (CCR) will hold its 19th annual auction Saturday, Oct. 21 at the Hills Prairie Livestock Auction Company, 1177...
MD Anderson team selected for national push to expand immunotherapy
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers...
MD Anderson expert to lead free Austin panel on Alzheimer’s disease
The University of Texas MD Anderson Cancer Center and Belmont Village Senior Living will present a free panel discussion in Austin exploring...
Registration open for Nov. 11 Boot Walk to End Cancer®
The University of Texas MD Anderson Cancer Center has opened registration for the second annual Boot Walk to End Cancer®, Saturday, Nov...
MD Anderson and BridgeBio Pharma launch Navire Pharma to develop targeted therapy for patients with difficult-to-treat cancer
The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company...
MD Anderson Cancer Center and Pfizer Oncology announce clinical collaboration
The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration...
Study shows diet and exercise improve treatment outcomes for obese pediatric cancer patients
Diet and exercise may improve treatment outcomes in pediatric cancer patients, according to a study at The University of Texas MD Anderson...
Tibetan yoga practice may improve sleep quality for breast cancer patients receiving chemotherapy
Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving...
Researchers compose guidelines for handling CAR T cell side effects
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge...
MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on...
MD Anderson Cancer Center to provide free skin cancer screenings at 2017 TOUR Championship
As the official cancer center of the PGA TOUR, The University of Texas MD Anderson Cancer Center will provide complimentary skin cancer screenings...
Rogers Award honors William Atkinson for Excellence in Administration
William Atkinson is the 2017 recipient of the Julie and Ben Rogers Award for Excellence in Administration at The University of Texas MD Anderson...
Following Hurricane Harvey, MD Anderson maintains exceptional patient care, supports staff
Through dedicated teamwork, strategic planning and the support of its internal and external communities, The University of Texas MD Anderson...
Making Cancer History®: Free seminar returns to Atlanta
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Atlanta for the third time, 8:30-...
MD Anderson receives $7.5 million in CPRIT funding for research and facility support
The University of Texas MD Anderson Cancer Center this week was awarded $7.5 million from the Cancer Prevention and Research Institute of...
MD Anderson’s Keeling Center Open House set for April 21
The University of Texas MD Anderson Cancer Center’s Michale E. Keeling Center for Comparative Medicine and Research will open its doors to...
Obituary for Charles Aubrey LeMaistre, M.D.
Charles Aubrey LeMaistre, M.D.
1924-2017
Charles Aubrey “Mickey” LeMaistre, M.D., beloved physician, father, trusted friend...
Former MD Anderson President Dr. Charles A. LeMaistre Passes Away at 92
Charles Aubrey “Mickey” LeMaistre, M.D., past president of The University of Texas MD Anderson Cancer Center and a pioneering crusader against...
A Conversation With a Living Legend® honors international architect Santiago Calatrava
The 28th annual A Conversation With a Living Legend® in Dallas, Sept. 14 at the Hilton Anatole, honors architect, artist and engineer Santiago...
Checkpoint inhibitors fire up different types of T cells to attack tumors
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell...
MD Anderson ranked top cancer hospital in annual survey
The University of Texas MD Anderson Cancer Center again has ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals...
Concurrent chemotherapy, proton therapy improves survival in patients with advanced lung cancer
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy...
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down...
Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center...
MD Anderson announces new leadership structure
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative...
Study shows biomarkers can predict which ER-positive breast cancer patients respond best to first-line therapy
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard...
MD Anderson UTHealth Graduate School receives $10.5 million gift
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
Making Cancer History® Seminar returns to Aspen
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public...
MD Anderson and Convergent R.N.R. Ltd. establish alliance to further develop new radiation technology with potentially fewer side effects
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new...
Innovative therapy strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...
MD Anderson and Hitachi to collaborate in research for treatment of oropharyngeal cancer of the head and neck
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered...
Higher gut bacteria diversity tied to slower metastatic melanoma progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated...
Two combination therapies shrink melanoma brain metastases in more than half of patients
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
Combination therapy targets genetic mutation found in many cancers
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused...
Image-guided biopsies accurately identify breast cancer patients who achieve pathologic complete response following neoadjuvant therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast...
Study provides better understanding of how brain tumors ‘feed’
All cancer tumors have one thing in common – they must feed themselves to grow and spread, a difficult feat since they are usually in a tumor...
San Diego Zoo Kids brings world of animals to MD Anderson pediatric cancer patients
The University of Texas MD Anderson Children’s Cancer Hospital today debuted San Diego Zoo Kids, a new television channel for patients and...
Ellis Island Medal of Honor Presented to Ronald DePinho, M.D.
Ronald DePinho, M.D., professor of biology and former president, The University of Texas MD Anderson Cancer Center, is among the recipients...
HPV vaccine may reduce oral infections by as much as 88 percent
ABSTRACT: 6003
Researchers have found that the human papillomavirus (HPV) vaccine may reduce the rate of oral HPV infections in young...
MD Anderson convenes global network of cancer-fighting institutions
More than 800 cancer doctors, nurses and scientists from all over the world will gather at The University of Texas MD Anderson Cancer Center...
Andrew Sabin Family Fellows to receive $100,000 in research funding
The University of Texas MD Anderson Cancer Center named eight innovative researchers to the second annual class of Andrew Sabin Family Fellows...
American Dental Association and MD Anderson Announce Collaboration
The American Dental Association (ADA) and The University of Texas MD Anderson Cancer Center today announced a joint effort to improve patient...
MD Anderson names Ben Melson new chief financial officer
The University of Texas MD Anderson Cancer Center has announced that Ben Melson will become the institution’s senior vice president and chief...
MD Anderson genetics expert Guillermina Lozano elected to National Academy of Sciences
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the prestigious National...
UT System hosts annual Eliminate Tobacco Use Summit
The University of Texas System convened its 2nd Annual Eliminate Tobacco Use Summit April 17-18 in Austin to enhance tobacco control...
Local restaurants and businesses bring prom to MD Anderson
The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party...
Jim Allison named one of TIME’s 100 most influential people
The University of Texas MD Anderson Cancer Center Chair of Immunology Jim Allison, Ph.D., whose pivotal insight to attack cancer by treating...
Pathologic complete response to neoadjuvant therapy in certain breast cancer patients predicts low risk for local metastases
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and...
MD Anderson and Lion Biotechnologies announce strategic alliance to conduct clinical trials of TILs in multiple solid tumors
The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies...
Making Cancer History®: Free seminar returns to Midland
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Midland, for the second time, 11:...
MD Anderson, Oncora Medical team up to fight cancer with precision medicine alliance
Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a...
Stand Up to Cancer innovation grant funds MD Anderson microbiome study
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her...
Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger...
Protein identified as potential druggable target for pancreatic cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC),...
Minority colorectal cancer patients report higher burden of poor quality-of-life than whites
A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics...
Study provides path for new immunotherapy approaches to prostate cancer
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack...
Jerry Jeff Walker to headline April 29 Polo on the Prairie in West Texas
The 31st annual Polo on the Prairie, a U.S. Polo Association-sanctioned event benefiting cancer research and patient care programs at The...
MD Anderson expert to lead Dallas panels on Alzheimer’s disease
The University of Texas MD Anderson Cancer Center brings Jim Ray, Ph.D., head of Neuroscience, to Dallas on Thursday, April 20, to lead two...
Marshall E. Hicks named interim president of UT MD Anderson Cancer Center
University of Texas System Chancellor William H. McRaven announced today the appointment of Marshall E. Hicks, M.D., as interim president...
Advanced form of proton therapy shows promise for treating lung cancer recurrence
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment...
MD Anderson celebrates the mission of Kick Butts Day
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts...
Change in Leadership at MD Anderson
Ronald A. DePinho M.D., president of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven...
Statement from The University of Texas System Chancellor William H. McRaven
When Dr. Ron DePinho was named president of The University of Texas MD Anderson Cancer Center by the Board of Regents in 2011, ...
Functional brain training alleviates chemotherapy-induced peripheral nerve damage in cancer survivors
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...
MD Anderson to provide skin cancer screenings, cancer prevention education at Shell Houston Open
Cancer prevention specialists from The University of Texas MD Anderson Cancer Center will provide skin cancer screenings free to the public...
Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard...
Absent tumor-suppressors allow melanoma to thwart immunotherapy
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint...
MD Anderson study ties protein ‘reader’ ENL to common leukemia
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid...
Two migration proteins boost predictive value of pancreatic cancer biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic...
Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an...
Lung cancer cells susceptible to inhibitor treatment via newly discovered pathway
Next-generation cyclin dependent kinase 2/9 (CDK2/9) inhibitors offer a novel way to treat lung cancer with minimal toxic side effects on...
Gut bacteria associated with cancer immunotherapy response in melanoma
Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies...
Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...
MD Anderson receives $19.5 million in CPRIT funding for recruitment and prevention
The University of Texas MD Anderson Cancer Center this week was awarded $19.5 million from the Cancer Prevention and Research Institute of...
More patients with early-stage breast cancer may be able to avoid chemotherapy in the future
Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes...
MD Anderson designated first Project ECHO superhub for oncology
Recognizing a critical need to address disparities in cancer care, The University of Texas MD Anderson Cancer Center has been designated as...
Scientists identify aggressive pancreatic cancer cells and their vulnerability
Researchers have identified a gatekeeper protein that prevents pancreatic cancer cells from transitioning into a particularly aggressive cell...
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according...
MD Anderson to present Making Cancer History® Seminar in Indian Wells
The University of Texas MD Anderson Cancer Center returns to Southern California this month with its Making Cancer History® Seminar, 3:30-...
Researchers identify ‘synthetic essentiality’ as novel approach for locating cancer therapy targets
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which...
MD Anderson supports World Cancer Day with allies around the globe
In honor of World Cancer Day on Feb. 4, The University of Texas MD Anderson Cancer Center calls for health care providers, organizations,...
Dr. Stephen Hahn joins MD Anderson senior leadership team
The University of Texas MD Anderson Cancer Center today announced the appointment of Stephen Hahn, M.D., to the senior leadership role of...
MD Anderson and Guardant Health announce partnership to make comprehensive liquid biopsy part of oncology standard of care
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive...
MD Anderson welcomes FDA proposed rule to limit carcinogen levels in smokeless tobacco
The University of Texas MD Anderson Cancer Center fully supports the proposed rule released today by the U.S. Food and Drug Administration...
‘Collateral’ lethality may offer new therapeutic approach for cancers of the pancreas, stomach and colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known...
MD Anderson Submits Letter to the Editor of Wall Street Journal
Dear Editor:
A reduction in force is something no institution wants to do, and it was something we worked tirelessly to avoid at MD...
MD Anderson and Deerfield Management create Vescor LLC to develop novel therapeutics based on inhibiting autophagy for treatment of specific cancers
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by...
MD Anderson and nation’s cancer centers jointly endorse updated HPV vaccine recommendations
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united...
MD Anderson and EMD Serono enter three-year strategic collaboration to accelerate development of investigational oncology/immuno-oncology compounds
The University of Texas MD Anderson Cancer Center and EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and...
MD Anderson and Affimed announce clinical immuno-oncology development collaboration
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and...
Recommendation for the further treatment of Chinese Nobel Prize Laureate Liu Xiaobo
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, The University of Texas MD Anderson...